Post-GSK purchase, Tesaro readies for cancer clash with Merck

A new GlaxoSmithKline subsidiary is developing another cancer-fighting drug that it believes could go toe-to-toe with the current market leader, Merck ’s blockbuster drug Keytruda.

Source: bizjournals.com Health Care:Biotechnology headlines - March 19, 2019 Category: Biotechnology Authors: Allison DeAngelis Source Type: news